Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 15;10(6):339-344.
eCollection 2020.

Clinical utility of procalcitonin in bacterial infections in patients undergoing hematopoietic stem cell transplantation

Amit Bansal  1 , Preethi Jeyaraman  2 , S K Gupta  1 , Nitin Dayal  3 , Rahul Naithani  2
Affiliations

Clinical utility of procalcitonin in bacterial infections in patients undergoing hematopoietic stem cell transplantation

Amit Bansal et al. Am J Blood Res. .

Abstract

Background: Infections are major contributor to morbidity and mortality in patients undergoing bone marrow transplant (BMT).

Objective: To assess role of serum procalcitonin (PCT) as a useful biomarker for the infections and outcomes in these patients.

Methods: Retrospective observational study.

Results: Total 47 patients with febrile episodes were enrolled. Twenty patients underwent autologous BMT and 27 underwent allogeneic BMT. Bacterial infections were documented in 18/47 (38%) patients. Forty patients were neutropenic. The median fever duration was 10 days (range 3-30 days) in positive procalcitonin level group whereas it was 4 days (range 1-18) in negative group. This was statistically significant (P=0.000). Procalcitonin levels were high in 8/9 episodes of sepsis (P=0.029). Intensive care unit transfers and death were significantly higher in PCT positive group as compared to PCT negative group.

Conclusion: Serum procalcitonin levels provide prognostic information of worse outcome in patients undergoing HSCT.

Keywords: Bone marrow transplant; infection; procalcitonin.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Massaro KS, Macedo R, de Castro BS, Dulley F, Oliveira MS, Yasuda MA, Levin AS, Costa SF. Risk factor for death in hematopoietic stem cell transplantation: are biomarkers useful to foresee the prognosis in this population of patients? Infection. 2014;42:1023–1032. - PubMed
    1. Irene GC, Albert E, Anna BV, Rahinatu A, Silvana N, Silvana S, Ana G, Jordi L, Carolina CA, Miquel G, Carolina M, Javier B, Jorge S, Rodrigo M. Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching. Bone Marrow Transplant. 2020:1–10. - PMC - PubMed
    1. Sheth V, Volt F, Sanz J, Clement L, Cornelissen J, Blaise D, Sierra J, Michallet M, Saccardi R, Rocha V, Gluckman E, Chabannon C, Ruggeri A. Reduced-intensity versus myeloablative conditioning in cord blood transplantation for acute myeloid leukemia (40-60 years) across highly mismatched HLA barriers-on behalf of eurocord and the cellular therapy & immunobiology working party (CTIWP) of EBMT. Biol Blood Marrow Transplant. 2020;26:2098–2104. - PubMed
    1. Ok ZO, Kupeli S, Sezgin G, Bayram I. Comparison of different doses of granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2020;42:e738–e744. - PubMed
    1. Sharma A, Sitthi-Amorn J, Gavigan P, Wolf J, Agulnik A, Brenner A, Li Y, Johnson LM. Outcomes and disposition of oncology patients with non-neutropenic fever and positive blood cultures. J Pediatr Hematol Oncol. 2020 [Epub ahead of print] - PMC - PubMed